We’re on a Mission to Change the Future of Parkinson’s Disease

Combining cutting-edge data science, human genetics, a potentially best-in-class therapy, and an innovative patient-centered clinical approach, we are developing a precision medicine approach designed to improve the lives of people with Parkinson’s disease.

Learn About Our Company
Beige DNA spiral particles on a gray background
Neuron23 circular logo mark
IT’S ALL POSSIBLE.

For too long, Parkinson’s disease therapeutics have been one size fits all, while only treating some of the symptoms. We aim to change that by bringing the precision medicine revolution to Parkinson’s disease to address the underlying causes.

We’re Rewriting the Narrative
to Change the Future

Neuron23 Envisions a World Where Parkinson’s Disease Has a Treatment Designed with Breakthrough Science, Powered by Personalized Medicine

Our Science

Meet the Heart of Neuron23

We're a diverse team with proven success in both science and business, driven by one common goal: creating a new day for people living with Parkinson’s disease. Compassion is at our core, and we're on a focused mission to create a breakthrough that may address one of the largest unmet medical needs in neurology: a therapeutic approach to impact Parkinson’s disease progression.

Meet Our Team

Latest News

  • NEWS /

    Neuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox Foundation

    $2.5 million grant supports clinical trial activation and patient screening efforts for precision medicine approach targeting LRRK2-driven Parkinson’s disease at four clinical sites in Israel SOUTH SAN FRANCISCO, Calif. – June 17, 2026 – Neuron23® Inc., a clinical-stage biotechnology company on a mission to transform the future of Parkinson’s disease through precision medicine, today announced […]

    Read More
  • NEWS /

    Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease

    NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027 SOUTH SAN FRANCISCO, Calif. – June 24, 2025 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of […]

    Read More
  • NEWS /

    Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology

    SOUTH SAN FRANCISCO, Calif. – March 25, 2025 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in […]

    Read More
See All News

Be in the Room When History is Made

We're looking for team members with the drive to innovate and the talent to make it happen — those ready to meet us where we are and excited to help us advance the treatment paradigm for people with PD.

Current Opportunities